Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 29, 2020 at 09:53 am
Share
Honz Pharmaceutical Co., Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 631.912 million compared to CNY 762.855 million a year ago. Operating income was CNY 18.908 million compared to CNY 16.466 million a year ago. Net income was CNY 2.134 million compared to CNY 1.657 million a year ago. Basic earnings per share from continuing operations was CNY 0.0047 compared to CNY 0.0037 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.
HONZ PHARMACEUTICAL CO., LTD. 
